+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antibodies"

Wiskott-Aldrich Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Wiskott-Aldrich Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Recessive Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025 - Product Thumbnail Image

Recessive Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Xerostomia - Pipeline Insight, 2025 - Product Thumbnail Image

Xerostomia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Lyme Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Lyme Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Systemic Mastocytosis - Pipeline Insight, 2025 - Product Thumbnail Image

Systemic Mastocytosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anterior Uveitis - Pipeline Insight, 2025 - Product Thumbnail Image

Anterior Uveitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Rhinosinusitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Rhinosinusitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Otitis Media - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Otitis Media - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Seborrhoeic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Seborrhoeic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
From
From
Bioproduction Market - Global Strategic Business Report - Product Thumbnail Image

Bioproduction Market - Global Strategic Business Report

  • Report
  • December 2025
  • 380 Pages
  • Global
From
Microbial API - Global Strategic Business Report - Product Thumbnail Image

Microbial API - Global Strategic Business Report

  • Report
  • December 2025
  • 466 Pages
  • Global
From
Loading Indicator

The Antibodies market is a subset of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Antibodies are proteins produced by the body to fight off foreign substances, such as bacteria and viruses. They are used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and cancer. Antibodies can be used in combination with other drugs, such as steroids, to reduce inflammation and improve symptoms. They can also be used to target specific cells or proteins in the body, allowing for more targeted treatments. The Antibodies market is highly competitive, with a number of companies offering a variety of products. Companies such as AbbVie, Amgen, and Biogen are leading the way in developing and marketing antibodies for the treatment of immune-related conditions. Other companies, such as Genentech and Regeneron, are also active in the market, offering a range of products for different conditions. Show Less Read more